Bursa Yuksek Ihtisas Training and Research Hospital
Bursa, 16000, Turkey (Türkiye)
Location status: Recruiting
Recruiting
NCT Number: NCT07823400
MIECC vs Conventional Cardiopulmonary Bypass and Systemic Inflammation in CABG
This prospective observational study evaluates the effects of minimally invasive extracorporeal circulation (MIECC) and conventional cardiopulmonary bypass on systemic inflammatory response in patients undergoing coronary artery bypass graft surgery. Adult patients undergoing elective coronary artery bypass surgery will be observed according to the extracorporeal circulation technique used during surgery. Systemic inflammation will be assessed using routinely available hematologic inflammatory indices, including the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII). These parameters will be evaluated preoperatively, at postoperative 6 hours, at postoperative 24 hours, and at hospital discharge. The study will also evaluate selected perioperative and postoperative clinical outcomes in order to compare the inflammatory response associated with MIECC and conventional extracorporeal circulation.
Recruiting
Interested in participating?
Request InfoKey information
Conditions
Age range
30 year–70 year
Sex eligibility
All sexes
Study type
Observational
Primary location
About this study
Coronary artery bypass graft surgery performed with cardiopulmonary bypass is associated with activation of systemic inflammatory pathways. Contact of blood with the extracorporeal circuit, surgical trauma, ischemia-reperfusion injury, and perioperative factors may contribute to this response. Minimally invasive extracorporeal circulation systems are designed to reduce blood-air contact, circuit surface area, and hemodilution and may therefore attenuate the inflammatory response compared with conventional cardiopulmonary bypass.
In this prospective observational study, patients undergoing elective coronary artery bypass graft surgery will be evaluated according to whether minimally invasive extracorporeal circulation or conventional extracorporeal circulation is used during surgery. No treatment assignment will be made by the study protocol.
Inflammatory response will be assessed using neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and systemic immune-inflammation index calculated from routinely obtained laboratory measurements. Measurements will be evaluated preoperatively, at 6 hours after surgery, at 24 hours after surgery, and at hospital discharge. Perioperative variables and postoperative clinical outcomes will also be recorded for comparison between the two groups.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Age 30-70 years
- Patients undergoing elective coronary artery bypass graft surgery
- Patients in whom cardiopulmonary bypass is planned
- Written informed consent obtained
Exclusion criteria
- Emergency surgery
- Redo cardiac surgery
- Concomitant valve surgery
- Previous open heart surgery
- Preoperative renal and/or hepatic failure
- Malignancy
- Active infection or inflammatory disease-
Treatment and study plan
Minimally Invasive Extracorporeal Circulation
ProcedureUse of a minimally invasive extracorporeal circulation system during coronary artery bypass graft surgery as part of routine clinical care.
Conventional Cardiopulmonary Bypass
ProcedureUse of conventional cardiopulmonary bypass during coronary artery bypass graft surgery as part of routine clinical care.
Primary outcomes
-
Neutrophil-to-Lymphocyte Ratio (NLR)
Time frame: Preoperative baseline, 6 hours after surgery, 24 hours after surgery, and on the morning of hospital discharge, an average of 6 days after surgery.
NLR will be calculated from routine complete blood count values by dividing the absolute neutrophil count by the absolute lymphocyte count. Values will be compared between the MIECC and conventional cardiopulmonary bypass groups.
-
Platelet-to-Lymphocyte Ratio (PLR)
Time frame: Preoperative baseline, 6 hours after surgery, 24 hours after surgery, and on the morning of hospital discharge, an average of 6 days after surgery.
PLR will be calculated from routine complete blood count values by dividing the platelet count by the absolute lymphocyte count. Values will be compared between the MIECC and conventional cardiopulmonary bypass groups.
-
Systemic Immune-Inflammation Index (SII)
Time frame: Preoperative baseline, 6 hours after surgery, 24 hours after surgery, and on the morning of hospital discharge, an average of 6 days after surgery.
SII will be calculated as neutrophil count × platelet count / lymphocyte count using routine complete blood count values. Values will be compared between the MIECC and conventional cardiopulmonary bypass groups.
Study contacts
Contact information is provided by the study sponsor or research team.
Sponsors and collaborators
Lead sponsor
Bursa Yuksek Ihtisas Training and Research Hospital
Other Gov
Registry information
Official study title
Comparison of the Effects of Minimally Invasive and Conventional Extracorporeal Circulation on Systemic Inflammation Indices in Coronary Artery Bypass Surgery
Acronym: MIECC-CABG
Important dates
- Study start
- 2026
- Primary completion
- 2026
- Study completion
- 2027
- First posted
- Sep 16, 2026
- Registry last updated
- Sep 16, 2026
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Recruiting
Saphenous Vein as Y-composite Versus Aortocoronary Conduit for CABG
NCT05704296
Arterial Occlusive Diseases, Arteriosclerosis
Seoul, South Korea
View Trial Details
Recruiting
OPTIMIZE-APT: Tailored Versus Conventional Antiplatelet Therapy After Intravascular Imaging-guided Drug-eluting Stent Implantation
NCT05418556
Arterial Occlusive Diseases, Arteriosclerosis
Bucheon-si, South Korea
View Trial Details
Recruiting
PCCT-Defined High-Risk Plaque and Future Coronary Events: The PREDICT Study
NCT07822737
Arterial Occlusive Diseases, Arteriosclerosis
Beijing, China
View Trial Details
Recruiting
Flecainide Safety in Patients With Coronary Artery Disease and Atrial Fibrillation
NCT07405671
Arrhythmias, Cardiac, Arterial Occlusive Diseases
Aalst, Belgium
View Trial Details